ES2071488T3 - Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado. - Google Patents

Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado.

Info

Publication number
ES2071488T3
ES2071488T3 ES92904088T ES92904088T ES2071488T3 ES 2071488 T3 ES2071488 T3 ES 2071488T3 ES 92904088 T ES92904088 T ES 92904088T ES 92904088 T ES92904088 T ES 92904088T ES 2071488 T3 ES2071488 T3 ES 2071488T3
Authority
ES
Spain
Prior art keywords
intact
purification
growth factor
insulin
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92904088T
Other languages
English (en)
Inventor
Gregory C Holtz
Russell A Brierley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SIBIA Neurosciences Inc
Original Assignee
Salk Institute Biotechnology Industrial Associates Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Institute Biotechnology Industrial Associates Inc filed Critical Salk Institute Biotechnology Industrial Associates Inc
Application granted granted Critical
Publication of ES2071488T3 publication Critical patent/ES2071488T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Detergent Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE DESCRIBE UN METODO PARA LA RECUPERACION DE PEPTIDOS DE FACTOR-1 DE CRECIMIENTO DE LA INSULINA EQUIVALENTE MONOMERICA CORRECTAMENTE AISLADA E INTACTA, DESDE MEDIOS QUE CONTIENEN GRANDES CANTIDADES DE IGF-1. EL METODO COMPRENDE UNA SERIE DE PASOS DE ABSORCION Y EXPULSION, QUE EMPLEAN UNA COMBINACION DE ABSORBENTES DE INTERACCION HIDROFOBICA Y DE CAMBIO DE CATIONES. EL PEPTIDO IGF-1 PRODUCIDO ES ALTAMENTE PURO Y ES DESEABLE PARA EL USO EN UNA GRAN VARIEDAD DE APLICACIONES CLINICAS.
ES92904088T 1991-01-16 1992-01-15 Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado. Expired - Lifetime ES2071488T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64143091A 1991-01-16 1991-01-16
US07/785,171 US5231178A (en) 1991-01-16 1991-10-28 Method for the purification of intact, correctly-folded insulin-like growth factor-1

Publications (1)

Publication Number Publication Date
ES2071488T3 true ES2071488T3 (es) 1995-06-16

Family

ID=27093753

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92904088T Expired - Lifetime ES2071488T3 (es) 1991-01-16 1992-01-15 Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado.

Country Status (9)

Country Link
US (1) US5231178A (es)
EP (1) EP0567554B1 (es)
JP (1) JPH06505010A (es)
AT (1) ATE121099T1 (es)
AU (1) AU1194792A (es)
CA (1) CA2098183C (es)
DE (1) DE69202049T2 (es)
ES (1) ES2071488T3 (es)
WO (1) WO1992012993A1 (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612198A (en) * 1990-09-04 1997-03-18 The Salk Institute Production of insulin-like growth factor-1 in methylotrophic yeast cells
ATE220105T1 (de) * 1991-04-01 2002-07-15 Merck & Co Inc Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
US5451660A (en) * 1993-12-13 1995-09-19 Genentech, Inc. Method for purifying polypeptides
US5446024A (en) * 1993-12-17 1995-08-29 Genentech, Inc. Purification of insulin-like growth factor
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
EP0779927A1 (en) * 1994-09-08 1997-06-25 Chiron Corporation A method of improved production of insulin-like growth factor
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6756484B1 (en) * 1995-04-14 2004-06-29 Cephalon, Inc. IGF-I purification process
US5650496A (en) 1995-04-14 1997-07-22 Cephalon, Inc. IGF-I purification process
US7071313B1 (en) 1995-06-07 2006-07-04 Cephalon, Inc. Methods of purifying authentic IGF from yeast hosts
US7193042B1 (en) 1995-06-07 2007-03-20 Chiron Corporation Methods for purifying authentic IGF from yeast hosts
AU6167596A (en) * 1995-06-07 1996-12-30 Chiron Corporation Methods for purifying authentic igf from yeast hosts
SE9504019D0 (sv) 1995-11-13 1995-11-13 Pharmacia Ab Method for production of proteins
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
EP1500661A1 (en) 1998-06-01 2005-01-26 Genetech, Inc. Separation of protein monomers from aggregates by use of ion-exchange chromatography
JP2001218840A (ja) * 2000-02-14 2001-08-14 Kanegafuchi Chem Ind Co Ltd トランスフォーミング増殖因子βの吸着材、吸着除去方法および吸着器
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
US7771929B2 (en) * 2000-04-28 2010-08-10 Monogram Biosciences, Inc. Tag library compounds, compositions, kits and methods of use
US20040067498A1 (en) * 2000-04-28 2004-04-08 Ahmed Chenna Detection of nucleic acid sequences by cleavage and separation of tag-containing structures
AR036400A1 (es) * 2001-08-30 2004-09-08 Stem Cell Therapeutics Inc Regulacion combinada de la produccion de celulas nerviosas.
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
US20030054551A1 (en) * 2001-09-18 2003-03-20 Stem Cell Therapeutics Inc. Effect of growth hormone and IGF-1 on neural stem cells
US6849394B2 (en) * 2002-02-21 2005-02-01 Minitube Of America Compositions comprising reproductive cell media and methods for using such compositions
CA2492442A1 (en) * 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
EP1711512B1 (en) * 2004-01-30 2012-01-11 Amgen Inc. Process for purifying proteins
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
CA2556266A1 (en) 2004-02-13 2005-08-25 Stem Cell Therapeutics Corp. Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US7632924B2 (en) * 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
WO2006091231A2 (en) * 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP2399893B1 (en) 2004-12-22 2018-08-15 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0519430A2 (pt) 2004-12-22 2009-02-10 Ambrx Inc hormânio do crescimento humano modificado
EP1836298B1 (en) * 2004-12-22 2012-01-18 Ambrx, Inc. COMPOSITIONS OF AMINOACYL-tRNA SYNTHETASE AND USES THEREOF
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE
CN103520735B (zh) * 2004-12-22 2015-11-25 Ambrx公司 包含非天然编码的氨基酸的人生长激素配方
AU2006255122B2 (en) * 2005-06-03 2010-10-21 Ambrx, Inc. Improved human interferon molecules and their uses
AU2005335491B2 (en) * 2005-08-18 2010-11-25 Ambrx, Inc. Compositions of tRNA and uses thereof
WO2007036033A1 (en) 2005-09-27 2007-04-05 Stem Cell Therapeutics Corp. Oligodendrocyte precursor cell proliferation regulated by prolactin
CN101400646A (zh) * 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
DK2339014T3 (en) * 2005-11-16 2015-07-20 Ambrx Inc Methods and compositions comprising non-natural amino acids
WO2007070659A2 (en) * 2005-12-14 2007-06-21 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
WO2007106987A1 (en) * 2006-03-17 2007-09-27 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
EP2064333B1 (en) * 2006-09-08 2014-02-26 Ambrx, Inc. Suppressor trna transcription in vertebrate cells
JP5399906B2 (ja) * 2006-09-08 2014-01-29 アンブルックス，インコーポレイテッド 脊椎動物細胞用のハイブリッドサプレッサーｔｒｎａ
CN106008699A (zh) * 2006-09-08 2016-10-12 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
CN107501407B (zh) 2007-03-30 2022-03-18 Ambrx公司 经修饰fgf-21多肽和其用途
EP1988154B1 (en) 2007-04-30 2013-08-21 Ajinomoto Co., Inc. Method for producing human insulin-like growth factor I
US8114630B2 (en) * 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
MX2010005317A (es) 2007-11-20 2010-06-02 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
MX344166B (es) 2008-02-08 2016-12-07 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
AU2009296267B2 (en) * 2008-09-26 2013-10-31 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
BR122012024318A2 (pt) 2008-09-26 2019-07-30 Ambrx, Inc. Polipeptídeos modificados de eritropoetina animal e seus usos
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EA030886B1 (ru) 2010-08-17 2018-10-31 Амбркс, Инк. Модифицированные полипептиды релаксина, содержащие некодируемую в природе аминокислоту, связанную с полимером, и их применение
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
AU2012272644B2 (en) 2011-06-23 2017-03-23 Rho Renewables, Inc. Recombinant production systems for aromatic molecules
SG10201605397PA (en) 2011-07-01 2016-08-30 Hoffmann La Roche Method For Separation Of Monomeric Polypeptides From Aggregated Polypeptides
CN114805532A (zh) 2014-10-24 2022-07-29 百时美施贵宝公司 修饰的fgf-21多肽及其用途
PE20191716A1 (es) 2017-02-08 2019-12-05 Bristol Myers Squibb Co Polipeptidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos
CN116368149A (zh) * 2020-11-05 2023-06-30 希米科控股有限公司 重组胰岛素样生长因子i的制造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG49718A3 (bg) * 1983-07-15 1992-01-15 Bio- Technology General Corp Метод за получаване на полипептид със супероксиддисмутазна активност
US4963665A (en) * 1986-01-07 1990-10-16 Washington University Human preproinsulin-like growth factor I
US4769361A (en) * 1986-08-07 1988-09-06 International Minerals & Chemical Corp. Method for purifying and isolating two ionic forms of somatomedin C
GB8819826D0 (en) * 1988-08-20 1988-09-21 Kabivitrum Ab Glycosylated igf-1

Also Published As

Publication number Publication date
AU1194792A (en) 1992-08-27
WO1992012993A1 (en) 1992-08-06
DE69202049T2 (de) 1995-08-24
DE69202049D1 (de) 1995-05-18
US5231178A (en) 1993-07-27
ATE121099T1 (de) 1995-04-15
CA2098183A1 (en) 1992-07-16
JPH06505010A (ja) 1994-06-09
CA2098183C (en) 2000-09-05
EP0567554A1 (en) 1993-11-03
EP0567554B1 (en) 1995-04-12

Similar Documents

Publication Publication Date Title
ES2071488T3 (es) Metodo para la purificacion de factor de crecimiento 1 analogo a la insulina intacto, correctamente plegado.
WO1996030520A3 (en) Synthetic hpv6/11 hybrid l1 dna encoding human papillomavirus type 11 l1 protein
ATE76412T1 (de) Homogenes erythropoietin.
EP0410207A3 (en) Stabilization of highly purified proteins
EP0261554A3 (en) Process for the purification of 1,3-propane diol
CA2157358A1 (en) Purification of Human Interleukin-10
ATE110704T1 (de) Verwendung von kohlenstoffmolekularsieben zur reinigung von chlorfluorkohlenwasserstoffen.
DE69101156D1 (de) Ein Verfahren zur Herstellung von veränderten adsorbierenden Kohlenstoffmolekularsieben.
EP0546110A4 (en) New insulin-like growth factor binding protein igfbp-5
NO974740D0 (no) IGF-1 renseprosess
ES2105033T3 (es) Metodo de purificacion de proteinas.
CA2137676A1 (en) Purification of fullerenes
DE60029542D1 (de) Verfahren zur Reinigung von 1,3-propandiol aus einem Fermentationsmedium
DE69132795D1 (de) Gereinigtes gp120, in dem seine natürliche konformation erhalten bleibt
ATE121077T1 (de) Neue organische nitrate und verfahren zu deren herstellung.
DE69313832D1 (de) Verfahren zur Herstellung von 2,4-Dihydroxydiphenylsulfon
FR2711323B1 (fr) Procédé d'élimination par adsorption d'hydrocarbures contenus dans l'air.
DE69208556D1 (de) Reinigung von 1,1,1,2-Tetrafluorethan
DE69214937D1 (de) Verfahren zur herstellung von gereinigten 2,6-naphthalindicarbonsäuren
DE59004488D1 (de) Verfahren zur Herstellung eines stabilen Faktors VIII.
ATE141615T1 (de) Neue peptid-derivate mit bradikyninantagonischer wirkung, verfahren zur deren herstellung und pharmazeutische zubereitungen die sie enthalten
AU1239795A (en) Purified stable liquid prealbumin
AU2478292A (en) Purification of factor xiii
AU3840695A (en) Novel alpha,alpha,alpha',alpha'-tetrachlorobicarboxylic acids, process for producing them and medicaments containing them
DE68922361D1 (de) Verfahren zur Herstellung von 2,6-Naphthalendicarbonsäure.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567554

Country of ref document: ES